Sector News

Lonza cuts 125 jobs as it moves cell work from U.S. plant

March 5, 2018
Life sciences

The decision by Swiss drugmaker Lonza to move cell-therapy work out of U.S. facility that was hit by an FDA warning letter last year will cost the plant about 125 jobs.

The CDMO recently said that it would concentrate its gene and cell therapy work at “centers of excellence.” Its sites in Pearland, Texas, and Geleen/Maastricht in the Netherlands will handle process and analytical development, as well as clinical and commercial supply, while sites in Portsmouth, New Hampshire and Singapore will do clinical and commercial manufacturing sites.

As a result, cell therapy work is being moved out of its site in Walkersville, Maryland, which was cited by the FDA last year. The Maryland site will concentrate on its bioscience solutions work providing custom and off-the-shelf media solutions.

John Mosack, senior site director for Lonza, told the Frederick News-Post that the move will affect about 125 of the 550 jobs at the site, but that the company hopes to keep some of those employees on as it expands its other work.

It already anticipated hiring nearly 60 employees this year. The company also is looking to see if some of those losing jobs might transfer to other Lonza sites.

The warning letter was issued last year after Lonza halted some production because of sterility problems with a cell therapy product it was producing for a client. Lonza first learned about the issue after “product end-user notified the FDA of the issue,” Lonza spokeswoman Constance Ward said at the time. The FDA warning letter uncovered issues that included with validation and aseptic process simulations.

Lonza some years back ran into FDA concerns about its biologics operations at an API plant it had in Hopkinton, Massachusetts, which was cited in 2011 for a plethora of problems. The action created supply problems for a drug it manufactured there for French drugmaker Ipsen.

After struggling to get issues resolved, Lonza simply closed the plant, eliminated 250 jobs, and concentrated its biologics work at its extensive site in Visp, Switzerland.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).